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architecture and record limb movements: 1 night with
the patient already treated with dopaminergic agonist;
1 night after treatment withdrawal; and, last, 1 night
after reintroduction of the dopaminergic agonist com-
pound. The patient had a clear benefit from prami-
pexol, then a major recrudescence of restlessness in
both arms subsequent to pramipexol withdrawal, and
was relieved again when the molecule was adminis-
trated at 12 p.m. on the following day. VPSG, as well
as an electromyogram (EMG) on the extensor carpi
radialis (ECR) muscle were performed to record peri-
odic movements of the upper limbs.5 Surprisingly, a
repeated extension of the small finger was observed,
especially during pramipexol withdrawal (Fig. 1A,
insert 1b,c; or see Video). The upper limb movements
could occur unilaterally (right or left), bilaterally, or
extend to the lower limbs and were observed during
periods of wakefulness and non-REM sleep. EMG ac-
tivity of the ECR (Fig. 1, part 2; or see Video) fulfils
the American Academy of Sleep Medicine criteria for
PLM disorder, 6 apart from for their localization.
Discussion and Conclusions
Involvement of upper limbs in RLS, although poorly
known, is relatively frequent.7 We report on a case that
confirms that RLS can be limited only to the arms.
Remarkably, a repeated extension of the small finger,
mimicking the typical extension of the hallux, characteris-
tic of PLM, was noticed. One should be aware of the
upper limb variant of this syndrome, and that treatment
by dopaminergic agonists proves to be very efficient.
Legends to the Video
Video 1. Video montage illustrates periodic upper limb
movements and is taken directly from the video capture
during PSG. Insert shown is an enlargement of the original
video of the whole body, explaining the low resolution.
EEG recording: F, frontal; C, central; P, parietal; T, tem-
poral; O, occipital; uneven numbers, left. EOGD G2 and
EOGG G2: electrooculogram. MentþMent: chin EMG.
JbGþJbG; JbDþJbD: left and right anterior tibialis
EMG. DelDþDelD; DelGþDelG: right and left del-
toid muscle EMG. DphDþDphD; DphGþDphG:
right and left extensor carpi radialis EMG.
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ABSTRACT
Background: Sham surgery controls are increasingly
used in neurosurgical clinical trials in Parkinson’s dis-
ease (PD) but remain controversial. We interviewed par-
ticipants of such trials, specifically examining their
understanding and attitudes regarding sham surgery.
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Methods: We conducted semistructured qualitative
interviews with participants of 3 sham surgery–con-
trolled trials for PD, focusing on their understanding of
sham design, their reactions to it, its impact on deci-
sion making, and their understanding of posttrial avail-
ability of the experimental intervention and its impact
on decisions to participate.
Results: All subjects (n 5 90) understood the 2-arm
design; most (86%) described the procedural differen-
ces between the arms accurately. Ninety-two percent
referred to scientific or regulatory reasons as rationales
for the sham control, with 62% specifically referring to
the placebo effect. Ninety-one percent said posttrial
availability of the experimental intervention had a
strong (48%) or some (43%) influence on their decision
to participate, but only 68% understood the conditions
for posttrial availability.
Conclusions: Most subjects in sham surgery–controlled
PD trials comprehend the sham surgery design and its
rationale. Although there is room for improvement, most
subjects of sham surgery trials appear to be adequately
informed. VC 2012 Movement Disorder Society
Key Words: sham surgery; gene therapy; Parkinson’s
disease; bioethics
Sham surgery controls are increasingly used in neu-
rosurgical clinical trials of interventions for Parkin-
son’s disease (PD).1–3 Unlike a pill placebo, sham
surgery is invasive, usually consisting of bilateral burr
holes (full or partial) with or without penetration of
the dura. The use of sham controls is supported by
most PD clinical researchers in North America despite
these controls being exposed to invasive sham surgery
because of the scientific advantages in controlling for
placebo effects.4 A recent review noted that there have
been 6 surgical interventions for PD that had initially
shown promise in open-label trials but that later
proved to be no more effective than placebo surgery.5
In 5 of 6 experimental therapies tested, the response
to active therapy was 50%–70% less in blinded trials
than in open trials; the open-label studies also tended
to underestimate the potential risks.
Yet sham surgery controls remain controversial.
Some scientists reportedly consider sham brain surgery
‘‘an expensive, potentially dangerous and possibly
unethical bit of biomedical theatrics.’’6 In Europe and
the United Kingdom, where sham controls are deemed
less acceptable than in the United States, a large clinical
trial of a fetal cell transplant treatment is under way
without the use of sham controls.6 One prominent rea-
son why sham controls have been deemed unacceptable
is a concern that vulnerable, elderly patients with incur-
able and debilitating illnesses may be exploited in such
research.7 In evaluating the ethics of this controversial
topic, it is important to incorporate the perspective of
those PD patients actually involved in such trials.
We interviewed persons who had agreed to partici-
pate in sham-controlled surgical trials for PD, examin-
ing their understanding and attitude toward sham
surgery controls, as well as toward the availability of
the experimental intervention to those in the sham
arm after the trial, a usual part of sham-controlled
studies that has created controversies of its own, as
subjects have sought the experimental intervention
even in negative trials.8
Patients and Methods
Participants
Participants were recruited from 3 sham-controlled
intervention trials for PD. We recruited 31 of 56 enroll-
ees (55%) at 5 sites from the STEPS trial1 and 30 of 43
enrollees (70%) at 7 sites of the CERE-120 trial3; they
were interviewed retrospectively, after their surgery
(details of their recruitment can be found in an earlier
report9). In the GAD study, sponsored by Neurologix,
Inc.,2 we interviewed 29 of the 45 enrollees (64.4%)
from 5 sites, of whom 24 were interviewed prospec-
tively, before surgery. All interviews were conducted
via telephone and were recorded and transcribed. Inter-
viewer notes were used for 1 interview because of tech-
nical difficulties in recording. The institutional review
boards of the University of Rochester and the Univer-
sity of Michigan reviewed the study and deemed this
study exempt from U.S. federal regulations.
Measures and Analysis
Conditional Probe Interview
The Conditional Probe Interview (CPI) is a semi-
structured qualitative interview guide designed to elicit
how the subjects made their decisions about participa-
tion.10 This article focuses on those questions in the
CPI that specifically address the subjects’ understand-
ing and attitudes toward the sham placebo design
(listed in Appendix 1). After all transcriptions were
checked for accuracy, standard content analysis proce-
dures were used, developing and refining codes in an
iterative fashion and resolving coding discrepancies
through group discussion.10
Results
Of the 90 subjects, most were white (n ¼ 88
[98%]), male (n ¼ 64 [71%]), married (n ¼ 66
[73%]), and well educated (n ¼ 52 with college degree
or higher [57%]). Average time since PD diagnosis
was 11.7 6 4.6 years.
Understanding Sham Surgery Research
Design, Rationale, and Procedures
All subjects showed a basic understanding of the
sham control design, that is, that there were 2 arms in
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their study, a placebo arm and a treatment arm. When
asked about the purpose of the control arm, the
answers varied in specificity (see Table 1).
Whereas some merely said that the FDA requires it,
others articulated the generic need (without specifi-
cally mentioning the placebo effect) for a comparison
arm:
‘‘I mean I’m not a world-renowned scientist or
something, but I know basically that to confirm it to
be a success, you have to have a control group’’
(STEPS, S23).
Others specifically mentioned the need to control for
the placebo effect in PD clinical trials:
‘‘The placebo effect is extremely strong in Parkin-
son’s for some reason in some individuals. So, you’ve
got to have a placebo group. The whole. . .All twelve
of those people in the phase I study could have been
affected by the placebo effect’’ (CERE-120, S7).
Overall, 92% of subjects provided an answer that
referred to the scientific or, less commonly, the regula-
tory rationale for the sham control arm.
Eighty-six percent of subjects described the proce-
dural differences between the study intervention and
the sham surgery groups accurately. These subjects
correctly contrasted the treatment arm, which involved
injection with the study agent into the brain, with the
placebo arm which involved only burr holes (and a sa-
line injection into the scalp for the GAD study).
Approximately 77% of subjects stated that the study
intervention arm has greater risks than the sham sur-
gery arm.
Attitudes Toward Sham Surgery Design
Overall, half the subjects reported that they initally
had a negative reaction to finding out that there would
be a sham surgery arm (see Table 2).
They mentioned being disappointed, concerned, or
apprehensive when they learned of the sham surgery
design: ‘‘[T]hat part of it is really a turn-off, a real big
one’’ (CERE-120, S18), ‘‘I had to think about that for
a little bit’’ (CERE-120, S2), and ‘‘I was discouraged’’
(GAD, S15). Surprisingly, 6 subjects had a positive
reaction after being informed that there would be a
sham surgery arm: ‘‘All good studies should be done
that way’’ (STEPS, S12), ‘‘. . .[T]he fact that there was
a placebo and it was double-blind. . .it did make me
more confident that. . .[i]t’s a professional study as
opposed to nonprofessional’’ (GAD, S5). Most of the
subjects with an initial negative reaction who indi-
cated the influence of this initial reaction on their deci-
sion (15 of 21 [71%]) said it did not negatively
influence their decision to participate.
When asked to comment on the invasive nature of
the control condition, most of the subjects’ comments
(79%) expressed views to the effect that they under-
stood the need for sham surgery, felt the risk was ac-
ceptable, trusted the researchers, or felt it was
acceptable in light of the later offer of the study inter-
vention. However, 14% of the comments from sub-
jects expressed some residual negative sentiments
about the sham arm.
Understanding and Attitudes Toward Later
Offer of Study Intervention
All 3 clinical trials offered the subjects in the sham
surgery arm the experimental intervention at the end
of the study period, with the condition that the study
intervention was proved to be safe and effective.
Although the majority of subjects understood the con-
ditions under which the study intervention would be
made available, a sizable minority (32%) wrongly
assumed that it would be offered without condition,
were not sure of the conditions, or expressed them-
selves in a way that did not allow a clear determina-
tion of whether they understood the conditions (Table
3).
The later offer of the experimental study interven-
tion had a strong impact on the enrollees’ decision to
participate, with nearly half (48%) saying that it was
a necessary or strong reason for his/her decision to
participate and an additional 43% saying it had some
influence.
Table 1. Understanding of sham control rationale and
procedures
n ¼ 90a
What is the purpose of having a sham surgery group?
Need to control for placebo effect 55 (61.8)
To make study legitimate/rigorous (no specific mention
of placebo effect)
25 (28.1)
Cannot determine from text if subject understands
purpose of sham surgery
3 (3.4)
FDA requires it 2 (2.2)
Subject not sure 2 (2.2)
Other 2 (2.2)
Describe the difference in procedures between those who receive sham
surgery and those who receive the [study intervention].
Describes differences accurately 67 (85.9)
Does not describe differences accurately 4 (5.1)
Subject cannot recall/not sure 6 (7.7)
Other 1 (1.3)
How are the risks faced by those in the [study intervention] group
different from the risks faced by those in the sham surgery group?
Those in [study intervention] group face greater risks 44 (77.2)
Those in sham surgery group face greater risks —
No difference/face same risks 10 (17.5)
Not sure 2 (3.5)
Other 1 (1.8)
aNumbers may not add to 90 for every question because of missing data
for some questions.
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Finally, 89% of subjects (among whom data were
available, 64) said it would be better to be in the
study intervention arm. Interestingly, 4 of the 6 sub-
jects who had a positive reaction to the sham design
still felt that the study intervention arm was the pref-
erable arm to be in. For example, although GAD
S24’s initial reaction to sham design was that ‘‘that
was the best. . .a marvelous way of handling it,’’ he
still preferred ‘‘the gene transfer.. . .I would think that
the genes have the best chance of doing something for
me to help out.’’
Discussion
Unlike a pill placebo, placebo surgery in a random-
ized controlled trial is not benign. Although to date
there appears not to have been serious adverse effects
from sham surgeries,11 an invasive control condition
in studies involving elderly persons with incurable ill-
nesses requires close ethical scrutiny. To inform this
issue, we examined the level of understanding of par-
ticipants of actual sham-controlled trials regarding key
design elements of a sham-controlled clinical trial.
There are several key findings. First, overall the sub-
jects were well informed regarding the sham surgery
design and its rationale. About two thirds of our sub-
jects articulated the rationale for the sham condition
with a fairly high degree of specificity (the need to
control for placebo effects), and the rest of the sub-
jects provided less specific but still accurate rationales
for sham surgery. A large majority of enrollees (86%)
also understood the differences in procedures between
the 2 arms. That nearly half the subjects (47%) ini-
tially had a negative reaction to the sham design sug-
gests that the subjects appreciated the implications of
a sham control design—especially because most also
understood that the study intervention arm is more
risky than the sham arm. Further, even those few who
had a positive reaction to the sham design provided a
sound rationale for their opinion. On the other hand,
there is room for improvement, as 14% of subjects
did not adequately describe the difference in proce-
dures between the sham arm and the intervention
arm, and 18% stated that the risks of the 2 arms were
the same.
Second, the subjects’ comments regarding the inva-
sive nature of the sham surgery arm suggested that
Table 2. Attitudes toward sham surgery
controls (n ¼ 90a)
What was your initial reaction to finding out there
would be a sham surgery group?
Negative reaction (disappointed, concerned,
surprised, etc.)
42 (47.2)
Neutral reaction (not surprised or concerned, etc.) 41 (46.1)
Positive reaction (strengthens study, makes study
more rigorous, etc.)
6 (6.7)
What influence did this initial reaction have on your decision, if any?
Negative influence on decision/made subject
more hesitant regarding participation
7 (15.6)
No negative influence on decision/neutral influence 35 (77.8)
Positive influence on decision 3 (6.7)
Usually placebos are risk-free (like taking a sugar pill), but sham surgery
placebos involve a neurosurgical procedure. What do you think about
the fact that sham surgery involves an invasive procedure? b
Understood need for control group, so accepted this 42 (42.0)
Risks of sham surgery seemed acceptable 22 (22.0)
Trusted researchers and so accepted this/deferred
to researchers
11 (11.0)
Acceptable in light of later offer of [study intervention] 4 (4.0)
Understood need for control group, but disagreed with
inclusion of sham surgery
8 (8.0)
Understood and accepted need for control group, but still
has some negative feelings concerning invasiveness
6 (6.0)
Other 7 (7.0)
aNumbers may not add to 90 for every question because of missing data
for some questions.
bFor this question, numbers refer to comments, not subjects, and exceed
the total number of subjects because some subjects made more than 1
comment.
Table 3. Understanding and attitudes toward later offer
of study intervention
n ¼ 90a
How are researchers going to decide if the [study intervention] will be
offered later to those who get the sham surgery initially?
If the intervention is determined to be potentially
beneficial and safe
60 (68.2)
Automatically offered/ no preconditions 13 (14.8)
Not sure what conditions must exist 10 (11.4)
Cannot determine if subject understands conditions 5 (5.7)
Please explain what influence [the posttrial offer of study intervention]
had on your decision to participate, if any.
Necessary or strong condition for participating 37 (48.1)
Some influence but not necessary 33 (42.9)
Did not influence decision 7 (9.1)
Other —
Do you think it would be better to be in the [study intervention] group
or the sham surgery group?
Active treatment group 66 (89.2)
Placebo group 3 (4.1)
Tried not to think about it 1 (1.4)
Other 4 (5.4)
Why [would that arm be better to be in]?b
Motivated by desire for direct personal benefit 33 (41.3)
Did not want to wait a year to receive
[study intervention]
18 (22.5)
Did not want to go through surgery twice 12 (15.0)
Each option has advantages 6 (7.5)
Wanted to wait and see what happened to
subjects who received [study intervention]
before subject received it
2 (2.5)
Did not want to be influenced by expectations,
so tried not to think about this
1 (1.3)
Other 8 (10.0)
aNumbers may not add to 90 for every question because of missing data
for some of the questions.
bFor this question, numbers refer to comments, not subjects, and exceed
the total number of subjects because some subjects made more than 1
comment.
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even if they had a negative initial reaction, they
accepted its rationale. Only about 14% of subjects’
comments (14 of 100 comments) reflected a residual
negative sentiment. Of those, 8 comments reflected the
view that although the subjects saw a need for a com-
parison arm, they disagreed with sham surgery as the
proper control. These subjects knowingly accepted the
sham arm despite their objections in order to partici-
pate in the trial. This raises the question of whether
these subjects were therefore less (because they had to
accept something they did not agree with) or more
(because they might have made a knowing trade-off)
‘‘voluntary’’ in their decisions to participate. Third,
the offer of posttrial availability of the study interven-
tion is very important to those who enroll in sham-
controlled trials in PD. Almost half said it was either
a necessary or a strong condition for their participat-
ing, with another 43% citing it as having ‘‘some influ-
ence.’’ However, a significant minority (32%) was
either mistaken or unclear about the conditions for
such an offer, and given its strong impact on decision
making, this is clearly an area in need of improve-
ment. Finally, the results reinforce the need to care-
fully distinguish between subject motivation and
subject understanding,10,12 as clearly demonstrated by
those subjects who recognized the need for the rigor-
ous study design, all the while desiring to be in the
intervention arm.
The study has limitations. First, the results are based
on qualitative coding of narrative texts. Although we
used methods to maximize reliability and reduce bias,
such coding involves judgment, and others may have
coded the texts differently. Second, the time of inter-
views varied, so that some subjects were interviewed
prospectively, whereas a majority were interviewed ret-
rospectively, some several years after surgery. However,
our sample included both prospective (n ¼ 24 enrollees)
and retrospective (n ¼ 66 enrollees) interviews, and the
responses were similar in both groups. Third, missing
data were a problem for a few of the follow-up probe
questions because of the nature of how we conducted
the interviews—allowing the subjects to lead the discus-
sion and thereby sometimes not asking all the probe
questions. Fourth, because the informed consent process
for these clinical trials was extensive, involving well-
educated subjects, one should be cautious about gener-
alizing these findings to other settings.
Most subjects in sham-controlled PD trials achieve
not only factual comprehension about the special fea-
tures of a sham control design—as required by
informed consent—but also achieve an appreciation of
the scientific and regulatory rationale for the design that
goes beyond the strict requirements of informed con-
sent. They are also able to coherently explain their deci-
sion making regarding research participation. But there
is clearly room for improvement, especially regarding
the conditions for posttrial availability of the study
interventions. Overall, informed consent concerns
regarding special features of sham-controlled trials in
PD, although needing some improvement, should not
be seen as a special ethical barrier to such studies.
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